John D Mendlein
Overview
Explore the profile of John D Mendlein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adams R, Fernandes-Cerqueira C, Notarnicola A, Mertsching E, Xu Z, Lo W, et al.
Cell Mol Immunol
. 2019 Dec;
18(6):1463-1475.
PMID: 31797905
His-tRNA synthetase (HARS) is targeted by autoantibodies in chronic and acute inflammatory anti-Jo-1-positive antisynthetase syndrome. The extensive activation and migration of immune cells into lung and muscle are associated with...
2.
Lo W, Gardiner E, Xu Z, Lau C, Wang F, Zhou J, et al.
Science
. 2014 Jul;
345(6194):328-32.
PMID: 25035493
Genetic efficiency in higher organisms depends on mechanisms to create multiple functions from single genes. To investigate this question for an enzyme family, we chose aminoacyl tRNA synthetases (AARSs). They...
3.
Zhou J, Wang F, Xu Z, Lo W, Lau C, Chiang K, et al.
J Biol Chem
. 2014 Jun;
289(28):19269-75.
PMID: 24898250
Inflammatory and debilitating myositis and interstitial lung disease are commonly associated with autoantibodies (anti-Jo-1 antibodies) to cytoplasmic histidyl-tRNA synthetase (HisRS). Anti-Jo-1 antibodies from different disease-afflicted patients react mostly with spatially...
4.
Mamluk R, Carvajal I, Morse B, Wong H, Abramowitz J, Aslanian S, et al.
MAbs
. 2010 Mar;
2(2):199-208.
PMID: 20190562
CT-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an Adnectin™, designed to inhibit vascular endothelial growth...